Compare Smith & Nephew plc (SNN) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs UBS Group AG Registered Ordinary Shares — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.31B), while UBS Group AG Registered Ordinary Shares trades at $47.69 (market cap $144.63B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 12.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| SNN | UBS | |
|---|---|---|
Market Cap | $11.31B | $144.63B |
Volume | 1,050,005 | 1,746,723 |
Sector | Health | Financials |
52-Week High | $37.17 | $55.72 |
52-Week Low | $26.42 | $36.41 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $14.35B | $311.50B |
Dividend Yield | 2.95% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
